Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a development that’s garnering attention in the healthcare sector, La Jolla Pharmaceutical (NASDAQ: LJPC ) has reportedly consented to be acquired by Innovia (NASDAQ: INVA ). As a result, LJPC stock ...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties, today announced the successful completion of its acquisition of Entasis Therapeutics Holdings Inc. (“Entasis”), an advanced late-stage clinical biopharmac...
Innoviva, Inc. ( INVA ), a diversified holding company has agreed to acquire the commercial-stage biotech La Jolla Pharmaceutical Company ( NASDAQ: LJPC ) for $6.23 per share in cash implying an enterprise value of ~$149M, the companies announced on Monday. Per the ter...
Acquisition to strengthen Innoviva’s infectious disease and hospital portfolio with addition of GIAPREZA ® and XERAVA ® Innoviva, Inc . (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovat...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the s...
The shares have collapsed since I took profits this past February. This put the company on my radar, as a cheap stock is definitionally safer than an expensive one. The problem is that the shares aren't cheap enough given the financial results the company has just posted. My track...
One of the largest tech deals in M&A history was announced last week. Chipmaker Broadcom entered into an agreement to acquire VMware for $69 billion in a cash or stock deal. Broadcom's acquisition of VMware will be reviewed by either the FTC or the DOJ, the Committee on Foreig...
Innoviva (NASDAQ:INVA) and Entasis Therapeutics Holdings (NASDAQ:ETTX) has entered into a definitive merger agreement under which Innoviva is to acquire all of the outstanding shares of Entasis at a price of $2.2/share in cash. Innoviva currently owns ~60% of the outstanding shares ...
Innoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cash Price per share in cash represents a 50% premium to Entasis’ closing price of $1.47 per share on January 31, 2022, the last date before Innoviva’s original bid b...
Pharmaceuticals and biotechnology are cheap relative to 11-year valuation averages. Life science tools and healthcare equipment are overvalued. IXJ: a global alternative to XLV. 10 stocks cheaper than their peers in May. For further details see: IXJ: Healthcare Dashb...
News, Short Squeeze, Breakout and More Instantly...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strate...